Evidence map›Paper›PMID 40601174›Full record

ArticleDiscover oncology2025

Mitochondrial pyruvate carrier inhibits tumor growth by Bmi1 ubiquitination in renal cell carcinoma progression.

Dan Jian, Nana Hu, Rong He, Le He, He Xiao, Xingqiao Peng, Yang Peng, Yuxin Yang, Xiaoyan Dai, Dong Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dan Jian *Cancer Center of Daping Hospital Army Medical University, No. 10 Changjiang Zhi Rd., Yuzhong Dist, Chongqing, 400042, China.
Nana Hu *Yu-Yue Pathology Scientific Research Center, Chongqing, 401329, China.
Rong HeCancer Center of Daping Hospital Army Medical University, No. 10 Changjiang Zhi Rd., Yuzhong Dist, Chongqing, 400042, China.
Le HeDepartment of Gastroenterology, Chongqing General Hospital, Chongqing University, Chongqing, 400013, China.
He XiaoCancer Center of Daping Hospital Army Medical University, No. 10 Changjiang Zhi Rd., Yuzhong Dist, Chongqing, 400042, China.
Xingqiao PengCancer Center of Daping Hospital Army Medical University, No. 10 Changjiang Zhi Rd., Yuzhong Dist, Chongqing, 400042, China.
Yang PengCancer Center of Daping Hospital Army Medical University, No. 10 Changjiang Zhi Rd., Yuzhong Dist, Chongqing, 400042, China.
Yuxin YangCancer Center of Daping Hospital Army Medical University, No. 10 Changjiang Zhi Rd., Yuzhong Dist, Chongqing, 400042, China.
Xiaoyan DaiCancer Center of Daping Hospital Army Medical University, No. 10 Changjiang Zhi Rd., Yuzhong Dist, Chongqing, 400042, China.
Dong WangCancer Center of Daping Hospital Army Medical University, No. 10 Changjiang Zhi Rd., Yuzhong Dist, Chongqing, 400042, China.
Yan FengCancer Center of Daping Hospital Army Medical University, No. 10 Changjiang Zhi Rd., Yuzhong Dist, Chongqing, 400042, China. 10446439@qq.com.
Nan DaiCancer Center of Daping Hospital Army Medical University, No. 10 Changjiang Zhi Rd., Yuzhong Dist, Chongqing, 400042, China. dn400024@tmmu.edu.cn.
Qian ChenCancer Center of Daping Hospital Army Medical University, No. 10 Changjiang Zhi Rd., Yuzhong Dist, Chongqing, 400042, China. 13chenqian@tmmu.edu.cn.

Funding

Chongqing Natural science Foundation General project CSTB2024NSCQ-KJFZMSX0030Chongqing Natural science Foundation General project cstc2023jcyj-msxmX0347Young Medical talent projects of Chongqing YXQN202466
6 · The paper itself

Abstract

Mitochondrial pyruvate carrier (MPC), composed of MPC1 and MPC2, plays a pivotal role in regulating cancer metabolism. While previous studies have implicated MPC1 in tumor progression, the specific function of MPC2 in renal cell carcinoma (RCC) remains largely unclear. In this study, we found that reduced MPC2 expression was significantly associated with advanced TNM stage and poor patient prognosis. Functional assays demonstrated that MPC2 suppresses RCC cell proliferation both in vitro and in vivo. Additionally, concurrent low expression of MPC2 and MPC1 was correlated with significantly shorter overall survival, suggesting their combined prognostic value. Gene set enrichment analysis indicated that both MPC1 and MPC2 are negatively associated with the Bmi1 signaling pathway. Mechanistically, inhibition of the MPC complex-either genetically or pharmacologically-led to increased Bmi1 protein levels by reducing its ubiquitin-mediated degradation. These findings identify the MPC complex as a potential tumor suppressor and prognostic biomarker set in RCC, functioning in part through modulation of Bmi1 stability.

Indexed as

Bmi1MPC1MPC2RCCUbiquitination

Identifiers

PMID40601174
PMCPMC12222602

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.